Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer and liver cancer. Provectus investigational oncology drug, PV , is an ablative immunotherapy under investigation in solid tumor cancers. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH , its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed Phase trials of PV as a therapy for metastatic melanoma, and of PH as a topical treatment for psoriasis. In addition, Provectus has begun a Phase trial as a therapy for metastatic melanoma. Information about these and the Company s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company s website at www.provectusbio.com.
Quote | Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT)
Last: | $0.1948 |
---|---|
Change Percent: | 0.0% |
Open: | $0.1948 |
Close: | $0.1948 |
High: | $0.1948 |
Low: | $0.19 |
Volume: | 138,051 |
Last Trade Date Time: | 04/23/2024 03:00:00 am |
News | Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT)
Research on breast, colorectal, head and neck, and testicular cancers Novel downregulation of WNK1 and Wnt signaling KNOXVILLE, TN, April 18, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announ...
2024-04-16 11:05:02 ET More on Provectus Biopharmaceuticals Provectus Biopharmaceuticals, Inc. (PVCT) Q1 2024 Earnings Call Transcript Financial information for Provectus Biopharmaceuticals Read the full article on Seeking Alpha For further details see: P...
Message Board Posts | Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT)
Subject | By | Source | When |
---|---|---|---|
NEWS -- Provectus Biopharmaceuticals Announces Publication of Activity | Paulness | investorshub | 04/20/2023 12:48:08 PM |
Strong today with decent volume at midday. | Plegee | investorshub | 02/28/2023 5:05:51 PM |
In for a few bushels. Thanks for | dranesthesia1 | investorshub | 02/28/2023 3:12:24 PM |
Yet another bounce off of $0.10 support. | Plegee | investorshub | 02/23/2023 7:55:34 PM |
Look at the tweet under the newsletter tweet https://twitter.com/ProvectusBio/s | Wehalls | investorshub | 01/12/2023 1:14:06 PM |
News, Short Squeeze, Breakout and More Instantly...
Provectus Biopharmaceuticals Inc Company Name:
PVCT Stock Symbol:
OTCMKTS Market:
Provectus Biopharmaceuticals Inc Website:
Research on breast, colorectal, head and neck, and testicular cancers Novel downregulation of WNK1 and Wnt signaling KNOXVILLE, TN, April 18, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announ...
Names Ed Pershing as Chief Executive Officer and Dominic Rodrigues as President KNOXVILLE, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced additions to its executive leader...
PV-10 demonstrated significant anti-tumor activity in vivo in head and neck cancers KNOXVILLE, TN, April 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from preclinical ...